Thyroid Eye Disease: Navigating Orbital Pathways to New Treatment...

1 West Wacker Drive,Chicago IL 60601

02 October, 2022

Description

Activity ChairRaymond S. Douglas, MD, PhD Professor of Surgery Division of Ophthalmology Director, Orbital and Thyroid Eye Disease Program Cedars-Sinai Medical Center Los Angeles, CA FacultyAndrea Lora Kossler, MD, FACS Director, Oculofacial Plastic & Orbital Surgery Associate Professor of Ophthalmology Byers Eye Institute at Stanford University School of Medicine Palo Alto, CA Jennifer M. Loh, MD Founder, Loh Ophthalmology Associates Board Member, Eye Physicians of Florida, LLP Miami, FL Prem S. Subramanian, MD, PhD Professor of Ophthalmology, Neurology, and Neurosurgery University of Colorado School of Medicine Vice Chair for Academic Affairs Division Head, Neuro-Ophthalmology University of Colorado Sue Anschutz-Rodgers Eye Center Aurora, CO OverviewThyroid eye disease (TED) is an autoimmune disorder believed to result from the stimulation of several receptors located in the orbital fibroblasts. It is frequently misdiagnosed, due to both its heterogeneous clinical presentation and a failure on the part of clinicians to understand the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at risk, as management of TED is most effective during the initial, active phase of the disease. However, differential diagnosis can be achieved with the assistance of imaging, and early treatment may limit disfigurement and reduce vision loss. Ophthalmologists should be knowledgeable about the presentation of these patients, which includes patients with dry eye, as well as conventional and new treatment options available for the treatment of patients with TED. In this case-based program, expert faculty will discuss these treatment options, including teprotumumab—the first and only medical agent approved by the US Food and Drug Administration for the treatment of TED. This program will include the unique, audience-engaging, educational gaming platform, A GameOn! Challenge. Agenda6:00 PM Registration and Dinner 6:30 PM Introduction and Pretest Raymond S. Douglas, MD, PhD 6:35 PM Thyroid Eye Disease: Pathogenesis and Differential Diagnosis Prem S. Subramanian, MD, PhD 6:45 PM Case Presentation: Differential Diagnosis Jennifer M. Loh, MD 6:55 PM Thyroid Eye Disease Treatment: Navigating Orbital Pathways Andrea Lora Kossler, MD 7:15 PM Case Presentation: Treating Thyroid Eye Disease Raymond S. Douglas, MD, PhD 7:35 PM GameOn! Challenge With your host, Raymond S. Douglas, MD, PhD 7:45 PM Posttest and Question & Answer 8:00 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Assess the pathogenesis of TED, including targets for treatment. Review the clinical presentation of TED, its symptomatology, and optimal methods to differentially diagnosis the condition to aide in early detection and treatment. Examine currently available TED treatments for their efficacy, safety, and ability to restore visual function and appearance. Target AudienceThe intended audience for this activity is ophthalmologists and other health care professionals involved in the management of patients with TED. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Horizon Therapeutics USA, Inc. This activity is not affiliated with the official program of AAO 2022. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity. Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.